Regeneron and partner Sanofi have notched another midstage milestone with their in-development allergy drug, a victory that affirms the hypothesis behind a treatment the companies believe could bring in billions.

…read more

Source: Regeneron’s would-be blockbuster completes the allergic circle with Phase II success